LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

Search

Harmony Biosciences Holdings Inc

Abrir

SetorSaúde

38.06 0.74

Visão Geral

Variação de preço das ações

24h

Atual

Mín

37.36

Máximo

38.18

Indicadores-chave

By Trading Economics

Rendimento

-5.8M

40M

Vendas

16M

200M

P/E

Médio do Setor

12.071

35.724

EPS

0.92

Margem de lucro

19.839

Funcionários

268

EBITDA

3M

59M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+33.38% upside

Dividendos

By Dow Jones

Próximos Ganhos

28 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

112M

2.2B

Abertura anterior

37.32

Fecho anterior

38.06

Sentimento de Notícias

By Acuity

50%

50%

172 / 372 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de ago. de 2025, 22:51 UTC

Ganhos

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 de ago. de 2025, 23:57 UTC

Ganhos

Trip.com Group 1H Rev $4.01B

27 de ago. de 2025, 23:57 UTC

Ganhos

Trip.com Group 1H Adj EPS $1.84

27 de ago. de 2025, 23:57 UTC

Ganhos

Trip.com Group 1H EPS $1.82

27 de ago. de 2025, 23:50 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 de ago. de 2025, 23:39 UTC

Ganhos

Correction to Nvidia Earnings Article -- WSJ

27 de ago. de 2025, 22:59 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de ago. de 2025, 22:59 UTC

Conversa de Mercado

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 de ago. de 2025, 22:58 UTC

Ganhos

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 de ago. de 2025, 22:57 UTC

Ganhos

South32 FY Free Cash Flow $192 Million

27 de ago. de 2025, 22:56 UTC

Ganhos

South32 FY Total Capital Expenditure $1.35 Billion

27 de ago. de 2025, 22:56 UTC

Ganhos

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 de ago. de 2025, 22:55 UTC

Ganhos

South32 Net Cash $123 Million at June 30

27 de ago. de 2025, 22:54 UTC

Ganhos

South32: Focused on Maintaining Strong Operating Momentum

27 de ago. de 2025, 22:53 UTC

Ganhos

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 de ago. de 2025, 22:53 UTC

Ganhos

South32 Extends Capital Management Program for 12 Months

27 de ago. de 2025, 22:52 UTC

Ganhos

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 de ago. de 2025, 22:51 UTC

Ganhos

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 de ago. de 2025, 22:51 UTC

Ganhos

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 de ago. de 2025, 22:50 UTC

Ganhos

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 de ago. de 2025, 22:50 UTC

Ganhos

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 de ago. de 2025, 22:45 UTC

Ganhos

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 de ago. de 2025, 22:44 UTC

Ganhos

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 de ago. de 2025, 22:44 UTC

Ganhos

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 de ago. de 2025, 22:43 UTC

Ganhos

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 de ago. de 2025, 22:43 UTC

Ganhos

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 de ago. de 2025, 22:42 UTC

Ganhos

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 de ago. de 2025, 22:42 UTC

Ganhos

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 de ago. de 2025, 22:40 UTC

Ganhos

Sandfire Resources Net Debt $123 Million at June 30

27 de ago. de 2025, 22:40 UTC

Ganhos

Sandfire Resources FY Underlying Ebitda $527.7 Million

Comparação entre Pares

Variação de preço

Harmony Biosciences Holdings Inc Previsão

Preço-alvo

By TipRanks

33.38% parte superior

Previsão para 12 meses

Média 50.75 USD  33.38%

Máximo 70 USD

Mínimo 33 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Harmony Biosciences Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

8

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

29.8 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Very Strong Bearish Evidence

Sentimento

By Acuity

172 / 372 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.